Table 1 Clinical characteristics of patients with COVID-19 according to disease severity.
Total patients with COVID-19 (n = 160 [100%]) | Asymptomatic/mild (n = 139 [86.9%]) | Severe/critical (n = 21 [13.1%]) | P-value | |
|---|---|---|---|---|
Age, years, median (IQR) | 68 (57–78) | 66 (55–77) | 78 (71–82) | 0.001 |
≧70, n (%) | 71 (44.4) | 55 (39.6) | 16 (76.2) | <0.001 |
Female, n (%) | 62 (38.8) | 58 (41.7) | 4 (19.0) | 0.08 |
ECOGPS ≧ 2, n (%) | 22 (13.8) | 14 (10.1) | 8 (38.1) | 0.002 |
Modified CCI except malignancy ≧ 2, n (%) | 24 (15.0) | 13 (9.4) | 11 (52.4) | 0.004 |
Relapsed or refractory condition, n (%) | 28 (17.5) | 20 (14.4) | 8 (38.1) | 0.018 |
Background hematological disease, n (%) | ||||
Lymphoid neoplasms | 108 (67.5) | 90 (64.7) | 18 (85.7) | 0.078 |
B-cell lymphoma | 64 (40.0) | 50 (36.0) | 14 (66.7) | 0.015 |
Plasma cell dyscrasia | 28 (17.5) | 25 (18.0) | 3 (14.3) | 1 |
Others | 16 (10.0) | 15 (10.8) | 1 (4.8) | 0.69 |
Myeloid neoplasms | 35 (21.9) | 34 (24.4) | 1 (4.8) | 0.047 |
Benign hematologic disorders | 17 (10.6) | 15 (10.8) | 2 (9.5) | 1 |
Treatment of underlying disease, n (%) | ||||
Ongoing treatment | 42 (26.2) | 20 (14.4) | 8 (38.1) | 0.018 |
Anti-CD20 antibody within 2 years | 41 (25.6) | 28 (20.1) | 13 (61.9) | <0.001 |
Bendamustine within 2 years | 11 (6.9) | 6 (4.3) | 5 (23.8) | 0.005 |
HSCT within 2 years | 2 (1.2) | 2 (100) | 0 (0) | — |
Time distribution of infection, n (%) | 0.067 | |||
January–March 2022 | 26 (16.2) | 20 (14.4) | 6 (28.6) | — |
April–June 2022 | 6 (3.8) | 4 (2.9) | 2 (9.5) | — |
July 2022–January 2023 | 128 (80.0) | 115 (82.7) | 13 (61.9) | — |
Vaccination doses before infection, n (%) | ||||
Two | 43 (26.9) | 35 (25.2) | 8 (38.1) | 0.289 |
≧Three | 117 (73.1) | 104 (74.8) | 13 (61.9) | — |
Bivalent vaccination against the Omicron variant | 21 (13.1) | 20 (14.4) | 1 (4.8) | 0.31 |
Pre-exposure prophylaxis with tixagevimab–cilgavimab | 1 (0.6) | 0 (0.7) | 0 (0) | — |
Anti-S level after infection, U/mL, median (IQR)a | 6705 (87.3–50118) | 14650 (758–52614) | 18.7 (0.4–866) | < 0.001 |
Seronegative after infection, n (%)a | 13 (9.5) | 6 (5.1) | 7 (35.0) | <0.001 |
Initial COVID-19 treatment, n (%) | <0.001 | |||
RDV | 19 (11.9) | 13 (9.4) | 6 (28.6) | — |
RDV + DEX | 4 (2.5) | 0 (0) | 4 (19.0) | — |
RDV + DEX+Tocilizumab | 1 (0.6) | 0 (0) | 1 (4.8) | — |
Ritonavir-boosted nirmatrelvir | 21 (13.1) | 20 (14.4) | 1 (4.8) | — |
Molnupiravir | 10 (6.2) | 7 (5.0) | 3 (14.3) | — |
Sotrovimab | 6 (3.8) | 4 (2.9) | 2 (9.5) | — |
Steroid pulse | 1 (0.6) | 0 (0) | 1 (4.8) | — |
Untreated | 98 (61.2) | 95 (68.3) | 3 (14.3) | — |
COVID-19 severity, n (%) | < 0.001 | |||
Asymptomatic | 19 (11.9) | 19 (13.7) | 0 (0) | — |
Mild | 120 (75.0) | 120 (86.3) | 0 (0) | — |
Severe | 16 (10.0) | 0 (0) | 16 (76.2) | — |
Critical | 5 (3.1) | 0 (0) | 5 (33.8) | — |
Outcome, n (%) | ||||
Hospitalization | 34 (21.3) | 13 (9.4) | 21 (100) | < 0.001 |
Death attributable to COVID-19 | 4 (2.5) | 0 (0) | 4 (19.0) | <0.001 |
Death due to other cause | 6 (3.7) | 1 (0.7) | 5 (23.8) | < 0.001 |
Death due to progression of underlying HD | 5 (3.1) | 1 (0.7) | 4 (19.0) | 0.001 |
